Validation of Proteomic Analyses for Allergic Asthma and Rhinitis

The VAPARA Study: Validation of Proteomic Analyses for Allergic Asthma and Rhinitis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01104012

Acronym

VAPARA

Enrollment

133

Registered

2010-04-15

Start date

2010-05-31

Completion date

2012-10-31

Last updated

2015-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Allergic, Rhinitis, Allergic

Brief summary

The purpose of this study is to verify and validate the intrinsic diagnostic value in terms of sensitivity and specificity of proteomic profiles determined during a pre-study for discriminating between allergy related asthma and allergy related rhinitis.

Interventions

BIOLOGICALClassification as asthmatic or rhinitis only via proteomic analysis

Proteomic profiles are established for each patient using plasma and serum samples

BIOLOGICALClassification as asthmatic or rhinitis only according to a metacholine test

A positive metacholine test indicating bronchial hyperresponsiveness is currently our Gold Standard for diagnosing asthma.

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* signed consent * never-smokers or non-smoking for at least 2 years + \< 5 packs per year * capable of understanding the study * patient is affiliated with a social security system * positive skin tests (at least one for Montpellier region pneumoallergens) * treated with nasal or inhaled corticoids, leucotriene receptor antagonists, anti-IgE, Theophylline, anti-histamines, sodium cromoglycate, beta-blockers, benzodiazépine, oral corticoids: all these treatments must be interrupted for at least 72 hours

Exclusion criteria

* Co-morbidities: none; no co-morbidities are accepted * dental infections (any) during the 3 months preceding the study * suspected alcoholism or drug abuse * chronic viral infection (hepatitis, HIV) * patient under guardianship

Design outcomes

Primary

Measure	Time frame	Description
Proteomic profile of each patient	One day (snapshot)	The attribution of a proteomic profile as either asthmatic or rhinitis. Proteomic profiles are determined accordig to the SELDI-TOF method. This is a transversal study validating proteomic profiles as a new diagnostic test.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026